Arstrogen

Arstrogen

Innovative drug development for autism, enhancing patient well-being through clinical expertise.

HQ location
Daegu, South Korea
Launch date
Enterprise value
$113m
  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor investor

€0.0

round
investor investor investor

€0.0

round
*

KRW2.0b

Valuation: KRW135.0b

Late VC
Total Funding000k
Notes (0)
More about Arstrogen
Made with AI
Edit

Astrogen is a pioneering company in the pharmaceutical industry, focusing on innovative drug development specifically for autism. The company leverages extensive clinical experience and patient needs to create groundbreaking treatments that go beyond traditional therapy. Astrogen serves a niche market of healthcare providers and patients dealing with autism, aiming to improve their quality of life. The business operates on a research and development model, investing heavily in clinical trials and scientific research to bring new drugs to market. Revenue is generated through the commercialization of these drugs, partnerships with healthcare institutions, and potential licensing deals. Astrogen's commitment to innovation and patient well-being positions it as a key player in the specialized field of autism treatment.

Keywords: autism, drug development, clinical trials, patient well-being, pharmaceutical, innovation, healthcare, R&D, commercialization, partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads